OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, January 11, 2017

Chemistry: Chemical con artists foil drug discovery : Nature News



 ar·ti·fact  ˈärdəfakt/
something observed in a scientific investigation or experiment that is not naturally present but occurs as a result of the preparative or investigative procedure.  "widespread tissue infection may be a technical artifact"
                                  ~~~~~~~~~~~~~~~~~~~~~~

Nature News

 Naivety about promiscuous, assay-duping molecules is polluting the literature and wasting resources, warn Jonathan Baell and Michael A. Walters.

Academic researchers, drawn into drug discovery without appropriate guidance, are doing muddled science. When biologists identify a protein that contributes to disease, they hunt for chemical compounds that bind to the protein and affect its activity. A typical assay screens many thousands of chemicals. ‘Hits’ become tools for studying the disease, as well as starting points in the hunt for treatments.
But many hits are artefacts — their activity does not depend on a specific, drug-like interaction between molecule and protein. A true drug inhibits or activates a protein by fitting into a binding site on the protein. Artefacts have subversive reactivity that masquerades as drug-like binding and yields false signals across a variety of assays1, 2.
These molecules — pan-assay interference compounds, or PAINS — have defined structures, covering several classes of compound (see ‘Worst offenders’). But biologists and inexperienced chemists rarely recognize them. Instead, such compounds are reported as having promising activity against a wide variety of proteins. Time and research money are consequently wasted in attempts to optimize the activity of these compounds. Chemists make multiple analogues of apparent hits hoping to improve the ‘fit’ between protein and compound. Meanwhile, true hits with real potential are neglected.

All pain, no gain
Some of the compounds that should ring the most warning bells are toxoflavin and polyhydroxylated natural phytochemicals such as curcumin, EGCG (epigallocatechin gallate), genistein and resveratrol. These, their analogues and similar natural products persist in being followed up as drug leads and used as ‘positive’ controls even though their promiscuous actions are well-documented8, 9....

 Very occasionally, a PAINS compound does interact with a protein in a specific drug-like way. If it does, its structure could be optimized through medicinal chemistry. However, this path is fraught — it can be difficult to distinguish when activity is caused by a drug-like mechanism or something more insidious.

(BRCA2) Prostate cancer team cracks genetic code to show why inherited disease can turn lethal



CNW Group
(press release)

TORONTO, Jan. 9, 2017 /CNW/ - Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50% of patients within five years.
The findings, published online today in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated cancers right from the get-go and therefore are resistant to therapy right up front, says co-principal investigator Dr. Robert Bristow, clinician-scientist at Princess Margaret Cancer Centre, University Health Network. He talks about the research at https://youtu.be/dXlntpaWtaI....

NCI - U.S.: New Drug Formulary Will Help Expedite Use of Agents in Clinical



(NIH)

  The NCI Formulary launched today with fifteen targeted agents from six pharmaceutical companies

The MATCH Study - Mindfulness/Tai Chi - University of Calgary/Princess Margaret Toronto



The MATCH Study | Mindfulness and Tai Chi for Cancer Health

 The University of Calgary and Princess Margaret Cancer Centre are conducting a study called MATCH comparing the benefits of these two group programs on well-being and functioning in cancer survivors

Are you Eligible?

In order to participate you must:

  • Be over the age of 18
  • Have been diagnosed with any type of cancer (stage I-III) except brain
  • Have completed active treatment (i.e. surgery, chemotherapy, radiation therapy) at least 4 months previously (ongoing hormonal therapies, AIs, tamoxifen, herceptin does not preclude)
  • Be able to attend classes at scheduled times
  • Have sufficient functional capacity to participate (judged by PAR-Q questionnaire, study staff, participant and participant’s physician)
  • Be able to speak, read, and write English sufficiently to participate in all activities.

You are unable to participate if you are experiencing any of the following:

  • Your cancer is metastatic or you are currently on chemotherapy.
  • You currently engage in meditation or tai chi one or more times per week
  • You have participated in the MBCR program in the past.

When is this happening?

Groups will begin every October, February and April beginning in 2016. Registration will begin in August 2016.

OA: Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario



 Blogger's Note: click on pdf for full access

open access

 Analysis was limited up to 2011, because this represented a time point prior to the widespread launch of PARP inhibitor trials in our region. In the province of Ontario, Local Health Integration Networks are responsible for regional health care administration and funding; the province is divided into 14 such geographically defined administrative health regions.
Based on the 2011 census, Ontario has approximately 6.58 million female residents older than 18 years. All Ontario residents are eligible to receive universal access to hospital care and physician services
The low consultation rates, as ascertained in our restricted dataset, suggest that a large gap exists between Cancer Care Ontario’s intention with the expansion of genetic testing in 2001 and the practice patterns in the province of Ontario.
Objective: In 2001, the province of Ontario expanded cancer genetic testing eligibility to include all women with high-grade serous ovarian carcinoma (HGSC) of the ovary, fallopian tube, and peritoneum. The aim of this study was to determine the proportion of women who attended genetics counseling for consideration of BRCA1/2 gene analysis. We also sought to examine if regional differences in consultation rate exist across administrative health regions in the province of Ontario.

Methods: We identified all women with a pathological diagnosis of HGSC in the province of Ontario between 1997 until 2011. Our primary outcome was the 2-year rate of genetics consultation following a diagnosis of HGSC. We compared consultation rates over time and geographical regions and applied multiple logistic regression to identify predictors of genetics consultation.

Results: Of the 5412 women with a diagnosis of HGSC over the study period, 6.6% were seen for genetics consultation within 2 years of diagnosis. Factors predictive of genetics consultation included history of breast cancer (odds ratio [OR], 3.56; 95% confidence interval [CI], 1.87-6.78), era of diagnosis (2009-2011 vs 1997-2000; OR, 10.59; 95% CI, 5.02-22.33), and younger age at diagnosis (OR, 0.95; 95% CI, 0.94-0.97 for each additional year). No regional differences in consultation rate were seen.

Conclusions: Despite an increasing rate across eras, a small proportion of women with HGSC undergo genetics consultation. Efforts are required to increase cancer genetics consultation in patients with HGSC in the province of Ontario.


OA: (Australasian) How does genetic risk information for Lynch syndrome translate to risk management behaviours? | Hereditary Cancer in Clinical Practice | Full Text



Hereditary Cancer in Clinical Practice | Full Text

Table of Contents

  Without preventive measures, the development of CRC amongst LS affected individuals is estimated at a lifetime risk of 10 – 74%, depending on sex and the MMR gene mutated [2, 3]. Female carriers are also at an increased risk of gynaecological cancers (GC), with an estimated lifetime risk for endometrial cancer of 14 – 71%, and 4 – 20% for ovarian cancer [2, 3].
Results
Thirty-three people were interviewed. Of the non-carriers (n = 16), 2 reported having apparently unnecessary colonoscopies, and 6 were unsure about what population-based colorectal cancer screening entails. Of the carriers (n = 17), 2 reported they had not had regular colonoscopies, and spoke about their discomfort with the screening process and a lack of faith in the procedure’s ability to reduce their risk of developing colorectal cancer. Of the female carriers (n = 9), 2 could not recall being informed about the associated risk of gynaecological cancers.

Conclusion

Non-carriers and female carriers of Lynch syndrome could benefit from further clarity and advice about appropriate risk management options. For those carriers who did not adhere to colonoscopy screening, a lack of faith in both genetic test results and screening were evident. It is essential that consistent advice is offered to both carriers and non-carriers of Lynch syndrome.

Tuesday, January 10, 2017

Requests for placement of ads on Ovarian Cancer and Us - that's a NO



Blogger's Note: Recently I have been getting an increased number of requests to place ads on this blog - these firms purport to pay for including their brands. It's a NO - will always be a NO. Give it up. Thanks.

New Clinical Trial Combines Two Methods to Defeat Ovarian Cancer: UNM



 Blogger's Note: there is no clinical trial reference # in this article

UNM Health Sciences Center
 Media Contacts
  Michele Sequeira
  505-925-0486
  MSequeira@salud.unm.edu

In a new clinical trial Adams is treating women whose ovarian cancer results from mutated BRCA genes with a drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.
The clinical trial is currently open to women with BRCA1 or BRCA2 mutations who have a higher risk of getting breast and ovarian cancers and may have relatives who had these cancers at young ages.
In pre-clinical studies, this combination therapy eliminated tumors and helped mice to live longer. The clinical trial now makes the therapy available to women with BRCA gene mutations whose ovarian cancer has returned.

Vitamin D and Cancer: An Unclear Relationship



Cancer Therapy Advisor

 Several recent studies attempted to determine the role of vitamin D supplementation in oncogenesis and cancer treatment. The relationship, however, remains unclear.
 According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.6 New randomized trials will need to be conducted to more fully understand the effect of vitamin D on cancer and its outcomes.

Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens



Abstract

 Preclinical data suggest that SERDs might be more effective than tamoxifen.

(Chicago) 2017 Ovarian Cancer National Conference: scholarships, hotel info and more!



2017 Ovarian Cancer National Conference: scholarships, hotel info and more!

 

Lynch syndrome - Genetics Home Reference



Lynch syndrome - Genetics Home Reference

 Lynch syndrome, often called hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited disorder that increases the risk of many types of cancer, particularly cancers of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the stomach, small intestine, liver, gallbladder ducts, upper urinary tract, brain, and skin. Additionally, women with this disorder have a high risk of cancer of the ovaries and lining of the uterus (the endometrium). People with Lynch syndrome may occasionally have noncancerous (benign) growths (polyps) in the colon, called colon polyps. In individuals with this disorder, colon polyps occur earlier but not in greater numbers than they do in the general population.

How a supplement maker tried to silence a Harvard doctor



science news

FORCE Annual Conference June 8-10, 2017 Orlando, Fla



FORCE Annual Conference > 2016 Conference Agenda

OA: Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective



Journal of Clinical Oncology

Neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) have been considered as ways to reduce surgical morbidity; however, the oncologic safety of these approaches has never been proven in a maximal effort setting of high surgical expertise.2,3 The inconsistent quality of the surgical trials that have addressed this matter so far; the broad variation in practice nationally and internationally; and the still unanswered questions of fragility scores, biomarkers, and valid predictors of operability have led to strong polarization and controversy worldwide, which gives a clear signal of the need for further evidence.
 Surgical outcome is affected not only by tumor biology and patient-related factors that cannot be influenced, but also by surgical and infrastructural expertise. The European Society of Gynecologic Oncology recently published criteria for the quality of AOC surgery and recommended PDS in patients expected to undergo upfront debulking to no residual tumor with a reasonable (expected) complication rate.30,31 Caution should be heeded to not recruit NAC-IDS cases to fill the gaps that arise from suboptimal expertise and inadequate infrastructural setting.

Fear of diagnostic low-dose radiation exposure is overstated, experts assert



Sciencenews


Journal Reference:
  1. Jeffry A. Siegel, Charles W. Pennington, Bill Sacks. Subjecting Radiologic Imaging to the Linear No-Threshold Hypothesis: A Non Sequitur of Non-Trivial Proportion. Journal of Nuclear Medicine, 2017; 58 (1): 1 DOI: 10.2967/jnumed.116.180182

Monday, January 09, 2017

OA (Australia): Messages to decision-makers from women with ovarian cancer Public report



open access pdf

Cigarette smoking is associated with adverse survival among women with ovarian cancer....



abstract:
Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies

 Cigarette smoking is associated with an increased risk of developing mucinous ovarian tumours but whether it is associated with ovarian cancer survival overall or for the different histotypes is unestablished. Furthermore, it is unknown whether the association between cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. In a large pooled analysis, we evaluated the association between various measures of cigarette smoking and survival among women with epithelial ovarian cancer. We obtained data from 19 case-control studies in the Ovarian Cancer Association Consortium (OCAC), including 9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate adjusted study-specific hazard ratios (HRs), which were combined into pooled hazard ratios (pHR) with corresponding 95% confidence intervals (CIs) under random effects models. Overall, 5,149 (57%) women died during a median follow-up period of 7.0 years. Among women diagnosed with ovarian cancer, both current (pHR = 1.17, 95% CI: 1.08-1.28) and former smokers (pHR = 1.10, 95% CI: 1.02-1.18) had worse survival compared with never smoking women. In histotype-stratified analyses, associations were observed for mucinous (current smoking: pHR = 1.91, 95% CI: 1.01-3.65) and serous histotypes (current smoking: pHR = 1.11, 95% CI: 1.00-1.23; former smoking: pHR = 1.12, 95% CI: 1.04-1.20). Further, our results suggested that current smoking has a greater impact on survival among women with localised than disseminated disease. The identification of cigarette smoking as a modifiable factor associated with survival has potential clinical importance as a focus area to improve ovarian cancer prognosis.

Medicine X 2017 ePatient Scholarship Program – Stanford Medicine X



Stanford Medicine X

Dr. Joseph Mercola Ordered to Stop Illegal Claims



Dr. Joseph Mercola 

Changes (01/05/2017) Ovarian Epithelial, FT, PP Cancer (NCI)



National Cancer Institute
 Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
 
Sections

Changes to This Summary (01/05/2017)

 
Revised a standard treatment option for advanced-stage ovarian epithelial cancer, FTC, and PPC to surgery followed by chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors.

The Surgery followed by chemotherapy and PARP inhibitors subsection was extensively revised.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

(VB-111) VBL Therapeutics Provides Year End 2016 Corporate Update



press release

  Founded in 2000, VBL is based in Or-Yehuda, Israel. 

 

| Source: VBL Therapeutics
TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017.
  • Following positive EOP2 meeting on VB-111 in ovarian cancer, VBL plans to launch a Phase 3 trial of VB-111 in Ovarian Cancer during the second half of 2017.
  • Interim analysis in the GLOBE pivotal study is expected in mid-2017, with top-line data expected in early 2018.
  • VBL's novel immune-oncology target to be disclosed during 1H 2017....
 VBL website

(new) myHealthRecord - Women's College Hospital Toronto



myHealthRecord

Were women foolish to follow Angelina Jolie into BRCA cancer gene testing?



science news opinion

Read with skepticism: News stories about Mediterranean diet and brain



Read with skepticism: News stories about Mediterranean diet and brain